Siegfried Grimm is a European and Swiss patent attorney and qualified before the UPC. He is heading Blum’s patent team on life science and material science since 2020 and is a board member since 2017. His technical expertise covers chemistry, pharmacy, nanotechnology and process technology.
Mr Grimm holds a master’s degree in chemistry from the Technical University of Aachen (Germany), where he also received his PhD. Right after his PhD, he joined a pharmaceutical development team at J&J, being responsible for pharmaceutical scale up in phase III development. He then started his career as in-house patent attorney, where he held positions at Bayer and Novartis prior to joining Blum.
Against this background, he combines his understanding of science and business perspectives into his advice to clients in IP matters. His key activities are in the fields of patent prosecution, drafting opinions, freedom-to-operate analyses and patent enforcement.
Early in his career, Mr. Grimm supported in-house litigation teams and now converts this expertise in supporting clients from pharmaceutical sector and material science sector in litigation before the Swiss Federal Patent Court.
In addition, Mr Grimm supports clients in medical approval matters before Swissmedic and he is very active in the field of supplementary protection certificates where he advises both domestic and international clients. He is author of the Swiss section of the SPC Handbook and participates in SPC initiatives of the Swiss Patent Office.
Year Joined Firm: 2005
Education/Alumni: PhD in Chemistry
